At the 12th annual PEGS Europe Summit, November 10th, CEO Geir Åge Løset presents Nextera’s NextCore drug discovery platform. The topic will encompass the novel way of developing drugs addressing the T-cell immunology space. Here, he will focus on Nextera’s NextCore platform for the development of TCR-like antibodies. These antibodies may prove to be important drugs towards HLA-associated targets, which can foster both cellular and protein therapies for immunological diseases. Read the abstract here: Developing Precision TCR-Like Specificities Using the NextCore Phage Display Platform.
Nextera invited to PEGS Europe.
